Pathogenesis roles and therapeutic targets of PBRM1 mutation in intrahepatic cholangiocarcinoma

Research Project

Project/Area Number	22K15336
Research Category	Grant-in-Aid for Early-Career Scientists
Allocation Type	Multi-year Fund
Review Section	Basic Section 47060:Clinical pharmacy-related
Research Institution	Kanazawa University
Principal Investigator	NguyenCanh Hiep 金沢大学, 医学系, 博士研究員 (10940835)
Project Period (FY)	2022-04-01 – 2025-03-31
Project Status	Granted (Fiscal Year 2022)
Budget Amount *help	¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000) Fiscal Year 2024: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000) Fiscal Year 2023: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000) Fiscal Year 2022: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Keywords	Cholangiocarcinoma / PBRM1 / Organoid / CRISPR/Cas9
Outline of Research at the Start	Intrahepatic cholangiocarcinoma is a heterogeneous cancer with dismal prognosis. Somatic mutations of Polybromo-1(PBRM1)are often found in iCCA. This study aims to clarify the mechanism how PBRM1 loss drives iCCA progression, search for novel therapeutic targets for PBRM1-deficiency iCCA.